ArticleMolecular oncology2017
ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways.
Article in Molecular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 196 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 4 syntheses or guidelines pooled it, 313 citations in OpenAlex.
- Diagnostic performance of circular RNAs in human cancers: A systematic review and meta-analysis.Molecular genetics & genomic medicine · 2019Pooled it
- Prognostic and diagnostic significance of circRNAs expression in hepatocellular carcinoma patients: A meta-analysis.Cancer medicine · 2019Pooled it
- Systematic Review and Meta-Analysis of the Utility of Circular RNAs as Biomarkers of Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2019Pooled it
- CircRNAs as biomarkers of cancer: a meta-analysis.BMC cancer · 2018Pooled it
- Circular RNAs in tumorigenesis: an insight into recent research in biogenesis and targeted tumor therapy.Cell cycle (Georgetown, Tex.) · 2026Review
- Role of Circular RNAs in Liver Diseases.International journal of medical sciences · 2026Review
- Therapeutic Potential of Circular RNAs as Targets for Cancer Treatment.Advanced pharmaceutical bulletin · 2025Review
- CircRNA ZFR promotes cell progression by regulating miR-96a-5p/SLC1A1 axis in hepatocellular carcinoma.Scientific reports · 2025Article
- Circular RNAs in cancer stem cells: Insights into their roles and mechanisms (Review).International journal of molecular medicine · 2025Review
- CircGRB14 Inhibits Proliferation and Promotes Apoptosis of Granulosa Cells in Chicken Follicle Selection Through Sponging miR-12264-3p and miR-6660-3p.International journal of molecular sciences · 2025Article
- Circular RNAs and Cancers.Advances in experimental medicine and biology · 2025Review
- CircSCMH1 Accelerates Sorafenib Resistance in Hepatocellular Carcinoma by Regulating HN1 Expression via miR-485-5p.Molecular biotechnology · 2025Article
- Non-coding RNAs as key regulators in hepatitis B virus-related hepatocellular carcinoma.Frontiers in immunology · 2025Review
- Ferroptosis: a new promising target for hepatocellular carcinoma therapy.Molecular and cellular biochemistry · 2024Review
- Invention of circRNA promoting RNA to specifically promote circRNA production.Nucleic acids research · 2024Article
- Leveraging gene correlations in single cell transcriptomic data.BMC bioinformatics · 2024Article
- Advanced approaches of the use of circRNAs as a replacement for cancer therapy.Non-coding RNA research · 2024Review
- CircRNA as an Achilles heel of cancer: characterization, biomarker and therapeutic modalities.Journal of translational medicine · 2024Review
- Context-specific eQTLs reveal causal genes underlying shared genetic architecture of critically ill COVID-19 and idiopathic pulmonary fibrosis.medRxiv : the preprint server for health sciences · 2024Article
- Engineering Synthetic circRNAs for Efficient CNS Expression.Methods in molecular biology (Clifton, N.J.) · 2024Article
136 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is increasing evidence that circular RNA (circRNA) are involved in cancer development, but the regulation and function of human circRNA remain largely unknown. In this study, we demonstrated that ZKSCAN1, a zinc finger family gene, is expressed in both linear and circular (circZKSCAN1) forms of RNA in human hepatocellular carcinoma (HCC) tissues and cell lines. Here, we analyzed a cohort of 102 patients and found that expression of both ZKSCAN1mRNA and circZKSCAN1 was significantly lower (P < 0.05) in the HCC samples compared with that in matched adjacent nontumorous tissues by reverse transcription PCR (RT-PCR). The low expression level of ZKSCAN1 was only associated with tumor size (P = 0.032), while the cirZKSCAN1 levels varied in patients with different tumor numbers (P < 0.01), cirrhosis (P = 0.031), vascular invasion (P = 0.002), or microscopic vascular invasion (P = 0.002), as well as with the tumor grade (P < 0.001). Silencing both ZKSCAN1mRNA and circZKSCAN1 promoted cell proliferation, migration, and invasion. In contrast, overexpression of both forms of RNA repressed HCC progression in vivo and in vitro. Silencing or overexpression of both forms of RNA did not interfere with each other. RNA-seq revealed a very different molecular basis for the observed effects; ZKSCAN1mRNA mainly regulated cellular metabolism, while circZKSCAN1 mediated several cancer-related signaling pathways, suggesting a nonredundant role for ZKSCAN1mRNA and circRNA. In conclusion, our results revealed two post-translational products (ZKSCAN1mRNA and circZKSCAN1) that cooperated closely with one another to inhibit growth, migration, and invasion of HCC. cirZKSCAN1 might be a useful marker for the diagnosis of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.